1,858 reports of this reaction
4.4% of all IFOSFAMIDE reports
#4 most reported adverse reaction
NEUTROPENIA is the #4 most commonly reported adverse reaction for IFOSFAMIDE, manufactured by Baxter Healthcare Corporation. There are 1,858 FDA adverse event reports linking IFOSFAMIDE to NEUTROPENIA. This represents approximately 4.4% of all 42,356 adverse event reports for this drug.
Patients taking IFOSFAMIDE who experience neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEUTROPENIA is moderately reported among IFOSFAMIDE users, representing a notable but not dominant share of adverse events.
In addition to neutropenia, the following adverse reactions have been reported for IFOSFAMIDE:
The following drugs have also been linked to neutropenia in FDA adverse event reports:
NEUTROPENIA has been reported as an adverse event in 1,858 FDA reports for IFOSFAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEUTROPENIA accounts for approximately 4.4% of all adverse event reports for IFOSFAMIDE, making it a notable side effect.
If you experience neutropenia while taking IFOSFAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.